Companies › Juro Sciences
1 active drug program in 1 registered trial: 1 Phase 2; Genitourinary; next expected readout Feb 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SFG-02 | – | Phase 2 | Participants With Underactive Bladder (UAB) | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07906106 | SFG-02 | Phase 2 | Participants With Underactive Bladder (UAB) | Genitourinary | Feb 2028 |
No annotated target.
–
Kira Pharmacenticals (US) Veloxis Pharmaceuticals Vifor Fresenius Medical Care Renal Pharma Vaneltix Pharma Tioga Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.